Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

151P - Association of the SLC30A8 rs13266634 variant with the colorectal cancer risk in the Taiwanese population

Date

27 Jun 2024

Session

Poster Display session

Presenters

CHUN-KANG LEE

Citation

Annals of Oncology (2024) 35 (suppl_1): S1-S74. 10.1016/annonc/annonc1477

Authors

C. LEE1, I. Chen2, Y. Lin2, Y. Chen2

Author affiliations

  • 1 Taichung Veterans General Hospital, Taichung/TW
  • 2 Taichung Veterans General Hospital, Taichung City/TW

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 151P

Background

Metabolic syndrome (MetS) is linked to an increased risk of colorectal cancer (CRC), with various single-nucleotide polymorphisms (SNPs) associated with MetS. However, whether SNPs related to MetS are also associated with CRC risk has not been systematically addressed. To explore this, we conducted a cross-sectional case-control study within a Taiwanese population.

Methods

This cross-sectional study enrolled a total of 58,091 Taiwanese participants, including 1,206 patients with CRC, using data from the Taiwan Precision Medicine Initiative (TPMI) database at Taichung Veterans General Hospital. The study collected genotyping information using the Affymetrix TWB 2.0 genome-wide SNP Array. Selected 2129 MetS-associated SNPs from previous GWAS databases were compared with TPMI data. Subsequently, 43 SNPs were chosen for a case-control study, and unadjusted analyses were performed. Three SNPs (rs4923461, rs7395662, and rs13266634) showed significance. A total of 1,206 CRC subjects and 4,824 age-gender matched controls were assessed the association between SNPs and the risk of CRC was evaluated using logistic regression models.

Results

Among the 58,091 participants, 26,655 had no diagnosis of cancer or MetS, while 1,206 participants were diagnosed with CRC. The carrier ratios of the MADD-FOLH1 rs7395662 and SLC30A8 rs13266634 variants were significantly higher in CRC patients, at 72.5% and 73.37% respectively (p=0.015 and p=0.002). In contrast, the carrier frequency of BDNF-AS rs4923461 was significantly higher in participants without cancer or MetS (72.04%, p=0.010). Among these three SNPs, participants carrying the SLC30A8 rs13266634 G allele showed a significantly higher CRC risk (OR: 1.01, 95% CI: 1.004-1.195, p=0.040) compared to those with the A allele. No significant differences were found in terms of age, gender, smoking, alcohol consumption, tumor markers, tumor location, pathology, clinical staging, or mortality.

Conclusions

In this cohort study, we confirmed the importance of the SLC30A8 rs13266634 G allele with an increased risk of CRC. The pleiotropic effects of this SNP on both MetS and CRC risk offer valuable insights for precision health strategies.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.